Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

30

Revenue 2017

Botox/Neuromodulator

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Botox/Neuromodulator was produced by Allergan.

Pharma funding and M&A in 2020

Pharma funding and M&A in 2020

a cool $63bn (which was also notable for putting the world’s best-selling drug Humira under the same roof as Botox).

Lundbeck gets US approval for migraine drug at heart of Alder takeover

Lundbeck gets US approval for migraine drug at heart of Alder takeover specialists aren’t rushing to switch wholesale from other migraine preventative therapies like Allergan’s Botox.

20 for 2020 – Five pharma companies to watch

20 for 2020 – Five pharma companies to watch year. Botox is facing tougher competition in the market from new migraine drugs as well as rivals in its medical aesthetics indications. ... The latter is still low level, however, and biosimilars to Botox are thought to be some years off the market.

Revenue growth at Ipsen numbs pain of palovarotene calamity

Revenue growth at Ipsen numbs pain of palovarotene calamity as Dysport (abobotulinumtoxinA), a rival to Allergan’s big-selling Botox brand.

Botox strength bolsters Allergan ahead of AbbVie takeover

Botox strength bolsters Allergan ahead of AbbVie takeover The US specialised therapeutics business – which include Botox – posted just 0.7% growth in the quarter to $1.82bn as medical aesthetics products Juvederm and Restasis posted sales declines. ... AbbVie has already announced plans to spin off the

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Visformatics (VISFO)

A team of strategic decision specialists with over 30+ years in the pharma space, we give you confidence through experience....

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...